Ireland - English - HPRA (Health Products Regulatory Authority)

dechra regulatory b.v. - amoxicillin trihydrate; potassium clavulanate - tablet - 400, 100 mg/tablet - amoxicillin and enzyme inhibitor

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - doxycycline hyclate, quantity: 115.4 mg (equivalent: doxycycline, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; indigo carmine; macrogol 4000 - infections caused by the following organisms; mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline alone, or in combination with topical agents). borreliae (relapsing fever). calymmatobacterium (donovania) granulomatis (granuloma inguinale). infection caused by the following gram-negative microorganisms: vibrio species (chlorea), brucella sp. (brucellosis; in conjunction with streptomycin), haemophilus ducreyi (chancroid), yersinia pestis (plague), francisella turarenis (tularaemia), bartonella bacilliformis (bartonellosis), bacteroides sp. when penicill

Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim vetmedica gmbh - doxycycline hyclate - tablet - 100 mg/tablet - doxycycline

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - doxycycline monohydrate, quantity: 104.1 mg (equivalent: doxycycline, qty 100 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; hydrogenated castor oil; povidone; magnesium stearate - infections caused by the following micro-organisms: mycoplasma pneumoniae (primary atypical pneumonia); rickettsiae (queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus); chlamydia psittaci (psittacosis); chlamydia trachomatis (lymphogranuloma venereum, trachoma, inclusion conjunctivitis). (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always elminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline, or in combination with topical agents.) borreliae (relapsing fever); calymmatobacterium (donovania) granulomatis (granuloma inguinale). doxycycline sandoz is indicated for the treatment of anthrax due to bacillus anthracis, including inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis (see dosage and administration). infections caused by the following gram-negative

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - doxycycline hyclate, quantity: 115 mg (equivalent: doxycycline, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; pregelatinised maize starch; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; sunset yellow fcf; quinoline yellow; macrogol 4000 - doxycycline is indicated in the treatment of infections caused by the following microorganisms: mycoplasma pneumoniae: primary atypical pneumonia; rickettsiae: queensland tick typhus, epidemic typhus fever, q fever, murine endemic typhus fever, australo-pacific endemic scrub typhus; chlamydia psittaci: psittacosis; calymmatobacterium (donovania) granulomatis: granuloma inguinale; chlamydia trachomatis: lymphogranuloma venereum, trachoma, inclusion conjunctivitis (doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. inclusion conjunctivitis may be treated with oral doxycycline alone or in combination with topical agents.); doxycycline is indicated in the treatment of infections caused by the following gram-negative microorganisms: vibrio species: cholera; brucella species: brucellosis (in conjunction with streptomycin); yersinia pestis: plague; francisella tularensis: tularaemia; bartonella bacilliformis: bartonellosis;

United States - English - NLM (National Library of Medicine)

avkare - tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - tetracycline hydrochloride 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: - upper respiratory tract infections caused by streptococcus pyogenes , streptococcus pneumoniae and hemophilus influenzae . note: tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. - lower respiratory tract infections caused by streptococcus

United States - English - NLM (National Library of Medicine)

harris pharmaceutical, inc - tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - tetracycline hydrochloride 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hcl capsules, usp and other antibacterial drugs, tetracycline hcl capsules, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. tetracycline hcl capsules, usp is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: - upper respiratory tract infections caused by streptococcus pyogenes , streptococcus pneumoniae and hemophilus influenzae . note: tetracycline hcl capsules, usp should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. - lower respiratory t

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

belmedpreparaty rue - tetracycline (tetracycline hydrochloride) - tablets film-coated - 100mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

belmedpreparaty rue - tetracycline (tetracycline hydrochloride) - tablets film-coated - 100mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

belmedpreparaty rue - tetracycline (tetracycline hydrochloride) - tablets film-coated - 100mg